← Bangkok Chain Hospital overview

Bangkok Chain Hospital vs Bangkok Dusit Medical Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bangkok Chain Hospital Public Company Limited (BCH.BK)

Q3 2026
▲2▼2

BCH mixed: SSO fee hike hope vs. profit drop and competition

  • Potential SSO fee hike A likely 5% increase in Social Security Office fees from 2027 could significantly boost profit, as SSO patients make up 38% of revenue. This is a key future earnings driver.

    It highlights a major positive catalyst for future profits.

  • Flood demand and broker upgrades Flood-related patient demand and broker upgrades with target prices of 12–13 baht supported the stock. July/August revenue grew 7–9%, and Q2 core profit beat expectations.

    It shows recent positive operational and market sentiment.

  • Q2 profit decline Q2/26 net profit fell 11.6% on lower revenue and higher costs, with outpatient revenue down 6.4%. This weakens the earnings outlook and investor confidence.

    It points to a key negative financial result.

  • Competition and downgrade CGSI downgraded BCH to sell, warning that 16 new premium public-hospital clinics will intensify competition, raise marketing costs, and poach doctors, pressuring self-pay and insurance revenue.

    It identifies a major competitive threat and analyst downgrade.

August 2026
▲2▼2

BCH: SSO Fee Hike Hopes and Flood Demand Offset Q2 Profit Drop

  • SSO fee hike still on track despite board delay Kasikorn says the two-week delay in electing the Social Security Office board won't stop a likely 5% rise in flat-rate payments from 2027. Since SSO is 38% of BCH's revenue, this is a big profit driver. Kasikorn rates BCH Buy with a 12.50 baht target.

    This is the main new positive catalyst for BCH's earnings and stock price.

  • Flood-driven patient demand boosts hospitals Asia Plus and InnovestX name BCH among hospitals that benefit from short-term demand during Bangkok flooding, as waterborne and other illnesses rise. They also see the flood as short-lived and recommend buying BCH on dips, which supports the stock.

    This is a new, near-term demand catalyst tied to current flooding.

  • Q2 profit fell 11.6% on lower revenue and higher costs BCH's Q2/26 net profit dropped 11.6% to 343 million baht as hospital revenue slipped 1.3% and the cost-to-revenue ratio rose to 70.8%. Outpatient revenue fell 6.4%. This shows the business was still weak in the quarter, weighing on the stock.

    This is the latest hard earnings result and a real counterweight to the positive news.

  • Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded BCH to sell, warning that 16 new premium clinics in public hospitals will intensify price competition, raise marketing costs, and poach doctors. This pressures BCH's self-pay and insurance business, and CGSI cut its earnings estimates and target price.

    This is a new competitive threat that could cap BCH's pricing power and margins.

Latest
▲2▼2

BCH: SSO Fee Hike Hopes and Flood Demand Offset Q2 Profit Drop

  • SSO fee hike still on track despite board delay Kasikorn says the two-week delay in electing the Social Security Office board won't stop a likely 5% rise in flat-rate payments from 2027. Since SSO is 38% of BCH's revenue, this is a big profit driver. Kasikorn rates BCH Buy with a 12.50 baht target.

    This is the main new positive catalyst for BCH's earnings and stock price.

  • Flood-driven patient demand boosts hospitals Asia Plus and InnovestX name BCH among hospitals that benefit from short-term demand during Bangkok flooding, as waterborne and other illnesses rise. They also see the flood as short-lived and recommend buying BCH on dips, which supports the stock.

    This is a new, near-term demand catalyst tied to current flooding.

  • Q2 profit fell 11.6% on lower revenue and higher costs BCH's Q2/26 net profit dropped 11.6% to 343 million baht as hospital revenue slipped 1.3% and the cost-to-revenue ratio rose to 70.8%. Outpatient revenue fell 6.4%. This shows the business was still weak in the quarter, weighing on the stock.

    This is the latest hard earnings result and a real counterweight to the positive news.

  • Premium public-hospital clinics threaten mid-tier private hospitals CGSI downgraded BCH to sell, warning that 16 new premium clinics in public hospitals will intensify price competition, raise marketing costs, and poach doctors. This pressures BCH's self-pay and insurance business, and CGSI cut its earnings estimates and target price.

    This is a new competitive threat that could cap BCH's pricing power and margins.

September 2026
▲3

BCH Recovery Gains Traction as Brokers Turn Bullish

  • Revenue and profit recovery July/August revenue rose 7–9% year-on-year and Q2 core profit beat forecasts by 13%, showing the business is bouncing back from a weak quarter. An interim dividend of 0.15 baht was also declared.

    This is the core new evidence that BCH's financial performance is improving, directly supporting the stock.

  • Broker upgrades and higher targets Krungsri, KKPS, Asia Plus, and CGSI all upgraded or raised their price targets to 12–13 baht, citing profit troughing, second-half recovery, Middle Eastern patients, and defensive appeal amid Fed rate hikes and a weak baht.

    Broker upgrades and target increases are a major new driver of investor sentiment and the stock price.

  • Ratchavej Ubon acquisition The acquisition of Ratchavej Ubon adds modest revenue of about 400–500k baht monthly. While small, it contributes to growth and shows BCH's expansion efforts.

    This is a new acquisition that adds incremental revenue and supports the growth narrative.

▲4

BCH Earnings Beat, Dividend, and Wave of Broker Upgrades

  • Q2 profit beat and interim dividend BCH's Q2 core profit of 343 million baht beat expectations by 13%, and the company declared an interim dividend of 0.15 baht per share. A profit beat plus cash returned to shareholders supports the stock price by showing the business is healthier than expected.

    This is a new, concrete positive event that directly boosts investor confidence and income appeal.

  • Profit trough passed, second-half recovery expected Finansia says BCH's profit has bottomed out and will recover in the second half, helped by returning Thai and Middle Eastern patients and a possible rise in social security fees. A clear recovery path can attract buyers and lift the stock.

    This new analyst call gives a forward-looking reason for the stock to rise beyond the past quarter.

  • KKPS and Asia Plus upgrade hospital sector, BCH a top pick KKPS raised the hospital sector to overweight with a 13 baht target on BCH, and Asia Plus named BCH a top play with a 12 baht target, citing seasonal illness and a likely social security fee hike. Upgrades and higher targets draw investors in.

    These new broker actions are fresh catalysts that can directly push the share price higher.

  • CGSI sees Q3 profit up 11%, BCH benefits from Middle East patients CGSI expects hospital group Q3 profit to grow 11% year-on-year, with BCH gaining from more Middle Eastern patients seeking complex care, putting nine-month profit at 71% of the full-year forecast. Strong patient mix supports earnings and the stock.

    This new estimate confirms the recovery trend and highlights BCH's specific advantage in foreign patients.

▲4

BCH Rides Revenue Recovery, SSO Fee Hike, and Defensive Demand

  • Revenue recovery and SSO fee hike drive profit outlook BCH's healthcare revenue is recovering, with July up 7% and August up 8-9% year-on-year. A potential increase in social security treatment fees is a big positive because 38% of revenue comes from SSO. This supports profit growth and a higher stock price.

    This is the core new fundamental driver for BCH's earnings and directly explains why the stock is moving.

  • Broker upgrades and target price raise Krungsri Securities recommends Buy on BCH with a 12.00 baht target, citing 3Q26F revenue growth of 6-7% and profit recovery. This upgrade and target price increase can attract investors and push the stock up.

    Analyst upgrades and target prices directly influence investor sentiment and demand for the stock.

  • Defensive demand amid Fed rate hike and weak baht After the Fed raised rates by 0.25%, brokers recommend defensive stocks like BCH. A weak baht (33.38 per dollar) also benefits hospitals by attracting foreign patients. This supports demand for BCH shares.

    Monetary policy and currency moves are macro forces that affect BCH's demand and pricing power.

  • M&A adds small revenue base BCH began consolidating Ratchavej Ubon Ratchathani Hospital from September 1, adding about 400,000-500,000 baht monthly revenue. While small now, it expands the network and supports long-term growth.

    This is a new corporate action that contributes to BCH's growth story and investor confidence.

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲2▼2

BDMS Q3 profit hits record as revenue rebounds, but foreign outflows and floods weigh

  • Record Q3 profit and revenue rebound BDMS reported a record quarterly profit near 4.5 billion baht, with August revenue up 9–10% and occupancy recovering to 65% after a weak Q2. Analysts upgraded target prices to 23.50–25.00 baht.

    This is the main positive driver of the stock's performance in Q3.

  • Weak baht and seasonal illness demand A weaker Thai baht boosted international revenue when converted back to baht, while a flu and COVID wave increased patient volumes. The WellEra wellness project also contributed to growth.

    These are key tailwinds that supported revenue and profit growth.

  • Foreign investor selling and high US yields Foreign investors sold 30.5 billion baht of Thai stocks in seven days, driven by Fed rate hikes that pushed US yields to 5.30%. This created downward pressure on BDMS and the broader market.

    This was a major negative force affecting stock price despite strong company results.

  • Floods and high interest rates cap market Flooding in parts of Thailand and elevated interest rates limited overall market gains and investor sentiment, preventing BDMS from fully benefiting from its operational momentum.

    These external risks acted as a counterweight to the positive company-specific news.

September 2026
▲3▼1

BDMS Surges on Record Q3 Profit and Upgraded Targets

  • Record Q3 Profit and Strong August Revenue BDMS is set to report record Q3 profit near 4.5 billion baht, with August revenue up 9-10% year-on-year, the first double-digit growth since early 2024, driven by Thai, insured, and Middle East patients.

    This is the core new financial performance that drove bullish sentiment and target upgrades.

  • Broker Target Upgrades Major brokers including TISCO, Krungsri, KGI, KKPS, Asia Plus, and CGSI raised their price targets to 23.50-25.00 baht, reflecting confidence in BDMS's earnings recovery and growth outlook.

    Broker upgrades directly influence investor sentiment and can drive buying interest.

  • Multiple Tailwinds Support Growth A weak baht, defensive appeal amid high rates, a flu/COVID wave, tighter FDA control of GLP-1 drugs, a cancer vaccine, flood demand, and a growing wellness market (target: 20% of revenue by 2035) are boosting BDMS's prospects.

    These factors collectively enhance demand and position BDMS favorably in the current environment.

  • Foreign Selling and Macro Risks Foreign investors sold 30.5 billion baht in seven days, and Fed rate hikes pushed US yields to 5.30%, while floods and high rates capped the broader market, posing risks to BDMS's stock performance.

    These external pressures could offset positive company-specific news and weigh on the stock.

Latest
▲3

Brokers pile into BDMS as Q3 profit recovery and defensive appeal build

  • Brokers raise BDMS targets on Q3 profit recovery KKPS, Asia Plus, CGSI and Land and Houses all back BDMS, with targets of 23.50-25.00 baht. They say hospital earnings passed their low point in Q2, August revenue grew 9-10% year-on-year, and Q3 profit should recover both year-on-year and quarter-on-quarter.

    Multiple fresh broker upgrades and higher targets are the main force lifting BDMS shares this period.

  • Flu wave and FDA drug rule lift patient demand Asia Plus says influenza cases jumped to 48,100 in mid-September from 21,753 the week before, with COVID-19 also rising, boosting hospital visits. Separately, tighter FDA control of GLP-1 weight-loss drugs pushes users into standard hospitals, where BDMS has a large network.

    These are new, concrete demand drivers that raise patient volumes and revenue per patient.

  • Cancer vaccine and flood demand add new growth angles Asia Plus flags BDMS as a main beneficiary of a Thai-developed personalized cancer vaccine that could cut treatment costs to about 1 million baht, lifting revenue per cancer patient. Asia Plus and InnovestX also name BDMS as a short-term flood beneficiary and a fast-recovery play.

    New technology and event-driven demand stories give investors fresh reasons to buy BDMS.

  • Defensive status helps, but foreign selling and floods weigh The Fed raised rates to 3.75-4.00%, pushing US 10-year yields to 5.30% and driving 30.5 billion baht of foreign selling in seven days. Brokers still name BDMS a defensive, low-volatility pick, but warn floods and high rates could cap the broader market.

    This is the real counterweight: money leaving Thai stocks limits how far BDMS can rise even with good news.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

© 2026 MarketDXWhy